Yamaha Motor: Consolidated Business Results Summary
8.8.2023 19:00:00 EEST | Business Wire | Press release
Yamaha Motor Co., Ltd. (Tokyo:7272) announces its consolidated business results for the first half of fiscal 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230808613856/en/
Yamaha Motor Headquarters, Iwata, Shizuoka, Japan (Photo: Business Wire)
Net sales for the consolidated accounting period for the first six months of the fiscal year ending December 31, 2023 were 1,226.4 billion yen (an increase of 157.5 billion yen or 14.7% compared with the same period of the previous fiscal year) and operating income was 142.8 billion yen (an increase of 40.3 billion yen or 39.4%). Ordinary income was 144.8 billion yen (an increase of 29.4 billion yen or 25.4%) and net income attributable to owners of parent was 105.3 billion yen (an increase of 22.3 billion yen or 26.9%). This is also the first time net income has exceeded 100 billion yen in a second quarter period.
For the first half-year consolidated accounting period, the U.S. dollar traded at 135 yen (a depreciation of 12 yen from the same period of the previous fiscal year) and the euro at 146 yen (a depreciation of 12 yen).
Market conditions during the second quarter were affected by factors that include subsiding outdoor recreation demand and a protracted economic recovery in China, but demand for large outboard motors and motorcycles remained strong. Compared to last year when the Company faced supply chain disruptions, marked improvements were made with product supply volumes and this resulted in higher sales. For operating income, higher unit sales as well as more pronounced effects from passing on costs to offset soaring prices for raw materials generated higher profits. Together with the positives of a weaker yen, led the Company to post record highs for net sales and incomes for a second quarter consolidated accounting period.
Forecast of Consolidated Business Results (Compared with the previous fiscal year)
Net Sales: 2,500 billion yen
(an increase of 251.5 billion yen or 11.2%)
Operating Income: 250.0 billion yen
(an increase of 25.1 billion yen or 11.2%)
Ordinary Income: 250.0 billion yen
(an increase of 10.7 billion yen or 4.5%)
Net Income Attributable to Owners of Parent: 180.0 billion yen
(an increase of 5.6 billion yen or 3.2%)
*Trading rate during the fiscal year: the U.S. dollar at 135 yen, the euro at 145 yen.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230808613856/en/
Contact information
Ayuko Kobayashi
Corporate Communication Division
Global PR Team
Yamaha Motor Co., Ltd.
TEL: +81(0)538-32-1145
ymc_pr@yamaha-motor.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom